Research Projects

Diabetic complications, driven by advanced glycation end-products (AGEs) and oxidative stress, remain a major therapeutic challenge. Tamarindus indica seed coat extract (TISC) has exhibited significant potency in its antidiabetic potential due to the high phenolic content but is limited in its therapeutic capabilities by poor bioavailability and the lack of targeting delivery strategies. Probiotics, known to improve gut barrier function and insulin sensitivity, offer a promising delivery vehicle, yet no study has explored their synergistic potential when fermented with TISC. The proposed proposal introduces a first-of-its-kind synbiotic strategy, where probiotic fermentation enhances TISC’s bioactive compounds while its polysaccharides act as prebiotics, creating a dual-action therapy against AGEs and dysbiosis. The novelty lies in three transformative gaps addressed by the proposal viz. leveraging microbial fermentation to unlock TISC’s hidden bioactivity (e.g., postbiotics with enhanced antiglycation effects), employing TISC’s own polysaccharides as a prebiotic-encapsulation matrix for targeted colonic delivery, and integrating multi-dimensional (LC-MS/MS, GC-MS) with AI-driven kinetic modeling to decode microbiota-phyto complex interactions. Unlike conventional approaches focusing on isolated probiotics or plant extracts, this convergent design merges phytochemistry, microbial biotechnology, and advanced drug delivery into a unified therapeutic platform. The hypothesis is that fermentation will enhance the bioactivity of TISC and give rise to postbiotics having better antiglycation and anti-inflammatory activity. Achieving this success in diabetes management will add a low-cost and culturally accepted therapy, especially where most of the 80% of diabetes patients currently live in low-resource regions. The proposal would also add to basic science by providing better insights into microbiota-aging end products interactions. Such an inference may also develop a precedent in upcycling harvest waste (tamarind seed coats) into high-value therapeutics. The project is expected, through integration of phytochemistry, microbiology, and drug delivery, to revolutionize synbiotic anti-AGE therapeutics with global health implications. The study’s innovation extends to its methodological breakthroughs. The study aims to (1) Assessment the effects of probiotic-fermented TISC on antiglycation (via inhibition assays and quantification of CML/pentosidine by LC-MS/MS) (2) Optimization of an encapsulated synbiotic formulation with assessments of stability and gastrointestinal survival, and (3) Confirmatory effectiveness in a diabetic rodent model, as assessed by measurement of HbA1c, AGE build-up levels, and gut microbiota modulation via SCFA profiling. Furthermore, Probiotic strains will be rigorously screened for glyoxalase-I/II activity, a rarely explored trait for AGE inhibition, and co-fermented with TISC under optimized bioreactor conditions to maximize postbiotic yield. The formulation’s novelty is underscored by a proprietary microencapsulation system combining whey protein and TISC-derived polysaccharides, designed to withstand gastric conditions while ensuring synchronized release of probiotics and phytochemicals in the colon. Preclinical validation in a diabetic rodent model will employ multispectral AGE imaging and machine learning to correlate gut microbiota shifts (via SCFA profiling) with glycation suppression. If successful, this research will deliver a fundamental insight into how microbial metabolism amplifies plant-derived antiglycation agents, and may be helpful in depicting a blueprint for "phyto-synbiotic" development, applicable to other underutilized botanicals. By transforming TISC, a culturally accepted but pharmacologically underexplored resource, into a clinically viable intervention, this work could redefine diabetes management in low-resource settings where the disease burden is highest.